Illumina
ILMN
$198.16
-3.38%
Illumina Inc. is a global leader in DNA sequencing and array-based technologies, providing instruments, consumables, and services that enable genomic analysis for life science research and clinical diagnostics. The company holds a dominant market position in the high-throughput sequencing space, with its platforms serving as the industry standard for whole-genome and targeted sequencing applications. Currently, the investor narrative centers on the company's strategic separation from Grail, its liquid biopsy subsidiary, and the subsequent refocusing on its core sequencing franchise, which has been met with renewed optimism as evidenced by a significant stock rally in recent months. The debate revolves around whether the company can sustain its growth trajectory amid competitive pressures and regulatory scrutiny, while also capitalizing on emerging opportunities in clinical genomics and population-scale sequencing.…
ILMN
Illumina
$198.16
Related headlines
Investment Opinion: Should I buy ILMN Today?
We rate ILMN as a Hold. The stock has strong fundamentals and a dominant market position, but at $205.10, it trades 18.9% above the average analyst target of $172.53, leaving limited upside. The consensus recommendation is 'Buy' with a mean rating of 2.35, but the wide target range ($95-$220) reflects high uncertainty. Our Hold rating is supported by the stock's trailing PE of 24.54x, which is at a 12% premium to the industry average of 22x, and its forward PE of 34.57x, which is above its historical average of 45x. The company's revenue growth of 4.8% YoY and gross margin of 66.7% are strong, but the valuation already prices in these strengths.
Sign up to view all
ILMN 12-Month Price Forecast
The AI model assesses ILMN as neutral with medium confidence. The company's dominant market position and high margins are offset by valuation concerns and near-term earnings headwinds. The stock's recent rally has outpaced fundamentals, and the forward PE suggests the market is pricing in a recovery that may not materialize. Upgrades to bullish would require evidence of accelerating growth and successful Grail separation, while downgrades would follow competitive share losses or regulatory setbacks.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Illumina's 12-month outlook, with a consensus price target around $193.05 and implied upside of -2.6% versus the current price.
Average Target
$193.05
0 analysts
Implied Upside
-2.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$113 - $230
Analyst target range
The wide range between the low and high targets ($95 to $220) underscores the high uncertainty surrounding Illumina's future, driven by factors such as the Grail spin-off, competitive dynamics, and regulatory developments. The high target likely assumes successful execution of the core sequencing strategy and robust growth in clinical applications, while the low target may reflect concerns about market share loss to competitors like Element Biosciences and MGI Tech. Recent institutional actions show a mix of ratings: JP Morgan upgraded from Neutral to Overweight in June, while Barclays maintains Underweight and Citigroup has a Sell, indicating a lack of consensus. The stock's current price above the average target suggests that the market is pricing in a more optimistic scenario than the analyst consensus, which could lead to a correction if expectations are not met.
Bulls vs Bears: ILMN Investment Factors
Illumina presents a compelling bull case with its dominant market position, accelerating revenue growth, and high margins, which have driven a remarkable stock rally. However, the stock now trades above the average analyst target, and the forward PE premium suggests near-term earnings pressure. The most critical tension is whether the company can sustain its growth momentum and successfully execute the Grail separation to justify the current valuation, or if competitive and regulatory headwinds will cause a correction. Currently, the bull case has stronger evidence given the fundamental strength and strategic clarity, but the valuation leaves little room for error.
Bullish
- Dominant Market Position: Illumina holds over 80% market share in high-throughput sequencing, with its platforms serving as the industry standard. This entrenched position provides pricing power and a strong competitive moat against smaller rivals.
- Accelerating Revenue Growth: Q1 2026 revenue grew 4.8% YoY to $1.091B, up from 1.9% growth in Q1 2025, indicating a clear acceleration. Sequencing revenue of $995M (91% of total) remains the core growth engine.
- High Gross Margins: Gross margin of 66.7% significantly exceeds the industry average of 55%, reflecting the company's premium pricing and efficient cost structure. This margin advantage supports robust profitability.
- Strategic Grail Separation: The planned spin-off of Grail removes a major overhang and allows management to refocus on the core sequencing business. This strategic clarity has driven a 99.7% stock rally over the past year.
Bearish
- Trading Above Analyst Targets: At $205.10, the stock is 18.9% above the average analyst target of $172.53, suggesting limited upside or potential for a correction if expectations are not met.
- Forward PE Premium: The forward PE of 34.57x is significantly higher than the trailing PE of 24.54x, implying the market expects earnings to decline in the near term, likely due to Grail separation costs.
- Competitive Threats: Emerging competitors like Element Biosciences and MGI Tech are gaining traction with lower-cost platforms, posing a risk to Illumina's market share and pricing power.
- Regulatory and Legal Overhang: Ongoing antitrust scrutiny and legal challenges related to the Grail acquisition and spin-off create uncertainty and potential financial penalties.
ILMN Technical Analysis
Illumina's stock has exhibited a powerful uptrend over the past year, with a 1-year price change of +99.69%, dramatically outperforming the S&P 500's +18.19% gain. The current price of $205.10 sits just 0.4% below its 52-week high of $205.93, and represents a 133% premium to its 52-week low of $88.00. This positioning near the upper end of the 52-week range indicates strong bullish momentum, though it also raises the risk of short-term overextension. The stock's relative strength versus the S&P 500 over the past year is a remarkable +81.50 percentage points, underscoring its leadership within the healthcare sector.
Beta
1.46
1.46x market volatility
Max Drawdown
-25.7%
Largest decline past year
52-Week Range
$88-$207
Price range past year
Annual Return
+109.3%
Cumulative gain past year
| Period | ILMN Return | S&P 500 |
|---|---|---|
| 1m | +5.0% | +1.7% |
| 3m | +42.5% | +4.7% |
| 6m | +47.7% | +10.4% |
| 1y | +109.3% | +21.9% |
| ytd | +47.5% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ILMN Fundamental Analysis
Illumina's revenue trajectory has been steadily improving, with Q1 2026 revenue of $1.091 billion representing a 4.8% year-over-year increase, up from the 1.9% growth seen in Q1 2025. The company's top line has grown from $1.041 billion in Q1 2025 to $1.091 billion in Q1 2026, with sequential growth from $1.083 billion in Q3 2025 and $1.057 billion in Q2 2025, indicating a consistent acceleration. Sequencing remains the primary growth driver, contributing $995 million in revenue (91% of total), while microarray sales of $96 million (9% of total) provide a stable secondary stream. The company's core business is demonstrating resilience, with management guiding for continued mid-single-digit growth as it expands its installed base and consumables pull-through.
Quarterly Revenue
$1.1B
2026-03
Revenue YoY Growth
+4.8%
YoY Comparison
Gross Margin
68.2%
Latest Quarter
Free Cash Flow
$989000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ILMN Overvalued?
Given Illumina's positive net income, the price-to-earnings (PE) ratio is the most appropriate valuation metric. The trailing PE stands at 24.54x, while the forward PE is 34.57x, indicating that the market expects earnings to decline in the near term, likely due to the Grail separation and associated costs. This forward premium suggests investors are pricing in a recovery in profitability beyond the current year. Compared to the industry average PE of 22x, Illumina trades at a 12% premium on a trailing basis, which is justified by its dominant market position and superior gross margins of 66.7% versus the industry average of 55%. The stock's current PE is well below its historical average of 45x over the past five years, suggesting that despite the recent rally, it remains reasonably valued relative to its own history.
PE
24.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 7x~161x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, Illumina carries a debt-to-equity ratio of 0.94, indicating moderate leverage that could strain cash flows if interest rates rise. The company's free cash flow of $989M TTM provides a cushion, but the forward PE of 34.57x implies the market expects earnings to decline, potentially due to separation costs. Revenue concentration is high, with 91% from sequencing, making the company vulnerable to any disruption in that segment. Operating margin of 19.9% is solid but could compress if competitive pricing pressures intensify.
FAQ
The key risks of holding ILMN are: 1) Competitive threats from Element Biosciences and MGI Tech, which could erode market share and pricing power. 2) Regulatory and legal issues related to the Grail acquisition and spin-off, which could result in fines or restrictions. 3) Financial risk from a debt-to-equity ratio of 0.94, which could strain cash flows if interest rates rise. 4) Valuation risk, as the stock trades above the average analyst target, leaving limited upside. The most severe risk is a competitive disruption that could cause the stock to fall toward the 52-week low of $88, a 57% downside.
The 12-month forecast for ILMN is mixed, with a base case target of $170-$190 (50% probability), a bull case of $210-$220 (30% probability), and a bear case of $95-$120 (20% probability). The base case assumes mid-single-digit revenue growth and successful Grail separation, while the bull case requires accelerated growth and market share gains. The bear case involves competitive losses and regulatory setbacks. The most likely scenario is the base case, with the stock consolidating near the average analyst target of $172.53.
ILMN is currently overvalued relative to its own history and analyst targets. The trailing PE of 24.54x is above the industry average of 22x, and the forward PE of 34.57x is significantly higher, indicating the market expects earnings to decline. The stock trades 18.9% above the average analyst target of $172.53, suggesting the market is pricing in a more optimistic scenario than the consensus. However, the PE is well below its 5-year historical average of 45x, so it is not as expensive as it has been in the past. The valuation implies the market expects strong growth and successful execution of the Grail separation.
ILMN is a good buy for investors with a long-term horizon who believe in the growth of genomics and are comfortable with the current valuation. The stock has strong fundamentals, with revenue growth of 4.8% YoY and gross margins of 66.7%, but it trades 18.9% above the average analyst target of $172.53, suggesting limited near-term upside. The biggest downside risk is a correction toward the 52-week low of $88, which would represent a 57% drop from current levels. For risk-tolerant investors, it could be a buy on any pullback toward the $170-$180 range.
ILMN is better suited for long-term investment due to its growth potential and strategic refocus on core sequencing. The stock has a beta that is not provided, but its 1-year volatility is high, with a 99.7% price change, making it unsuitable for short-term trading unless one is willing to accept significant risk. The company does not pay a dividend, so returns depend on capital appreciation. Given the earnings visibility from its dominant market position, a minimum holding period of 3-5 years is recommended to allow the Grail separation and growth initiatives to play out.